Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Oyster Point Pharma, Inc.
Protocol OPP-102 is a Phase 2, multicenter, randomized, controlled, double- masked study designed to evaluate the safety and efficacy of OC-01 (varenicline) nasal spray in subjects with NK. Approximately 100 subjects at least 18 years of age with a physicians' diagnosis of Stage 1 NK as defined by the Mackie Criteria and meeting all other study eligibility criteria will be randomized 1:1 and will receive OC-01 (varenicline)/ nasal spray or placebo nasal spray for 8 weeks three times daily (TID) as follows: * OC-01 (varenicline) nasal spray, 1.2 mg/mL * Placebo (vehicle control) nasal spray All doses will be delivered as a 50 microliter (µL) nasal spray.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
